Staging of Intestinal Lymphoma Using the Lugano Classification
Intestinal lymphoma should be staged using the Lugano classification system, which incorporates PET-CT as the gold standard imaging modality for FDG-avid lymphomas and applies a modified Ann Arbor staging framework with four stages (I, II, III, IV) based on anatomic extent of disease. 1
Core Staging Framework
The Lugano classification stages intestinal lymphoma as follows:
- Stage I: Lymphoma confined to a single extranodal site (the GI tract) 1
- Stage II: Lymphoma involving the GI tract with regional lymph node involvement (stage II1) or extending beyond regional nodes but still on the same side of the diaphragm (stage II2) 1
- Stage III: Lymphoma on both sides of the diaphragm or involvement of lymph nodes above the diaphragm 1
- Stage IV: Disseminated involvement of one or more extranodal organs beyond the primary GI site 1
Imaging Requirements
PET-CT is the preferred staging modality for FDG-avid intestinal lymphomas (particularly diffuse large B-cell lymphoma, which represents the majority of intestinal lymphomas). 1 Focal FDG uptake in the intestinal wall and associated lymph nodes consistent with lymphoma distribution is considered disease involvement. 1
For contrast-enhanced CT:
- Required when PET-CT shows bowel involvement to better distinguish lymphomatous tissue from normal bowel 1
- Necessary for accurate measurement of nodal size in clinical trials 1
- Up to six target lesions (nodes >1.5 cm or extranodal lesions >1.0 cm) should be measured in two diameters from different body regions 1
Key Staging Considerations for Intestinal Lymphoma
The Lugano system has demonstrated superior prognostic value compared to TNM and Musshoff staging systems for primary gastrointestinal DLBCL, serving as an independent prognostic factor for both progression-free survival (HR=4.987) and overall survival (HR=5.659). 2
Important staging elements include:
- Depth of tumor infiltration (T stage): Patients with T1-T2 disease show significantly better 5-year OS (96.15%) versus T3-T4 disease (67.92%) 3
- Regional lymph node involvement: Must be assessed via imaging 1
- Distant metastases: Particularly to liver, spleen, bone marrow, or other extranodal sites 1
Bone Marrow Assessment
Bone marrow biopsy can be omitted in patients with DLBCL when PET-CT is used for staging, as PET-CT adequately identifies marrow involvement in FDG-avid lymphomas. 1, 4 This represents a major departure from prior staging systems and reduces patient burden.
B Symptoms Classification
Unlike Hodgkin lymphoma, the A/B symptom designation is no longer routinely required for intestinal NHL staging under Lugano criteria, though B symptoms remain prognostically significant when present. 1, 4 B symptoms include fever >38°C, drenching night sweats, or unexplained weight loss >10% of body weight in 6 months.
Clinical Pitfalls
- Mantle cell lymphoma caveat: Despite being FDG-avid, PET-CT has low sensitivity and specificity for identifying bowel involvement in mantle cell lymphoma and should not replace endoscopic evaluation 1
- Variably FDG-avid histologies: Marginal zone lymphomas and other indolent subtypes should be staged with contrast-enhanced CT rather than PET-CT 1
- Stage migration: More sensitive PET-CT staging may upstage 10-30% of patients compared to CT alone, though this improves accuracy and prevents under-treatment 1
Prognostic Integration
The Lugano stage should be integrated with other prognostic factors including:
- LDH levels 2, 5
- ECOG performance status 2
- Number of extranodal sites 2
- International Prognostic Index (IPI) score 2
Lugano stage is an independent prognostic factor for both OS and PFS in secondary intestinal DLBCL patients, making it the most clinically relevant staging parameter. 5